Patents by Inventor Ruth Karen Moysey

Ruth Karen Moysey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Modified leukocyte Ig-like receptor family members (LIRs) with increased affinity for class 1 MHC and their uses in modulating T-cell activation
    Patent number: 8092807
    Abstract: The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a KD for the said given Class I pMHC of less than or equal to 1 ?M and/or has an off-rate (koff) for the said given Class I pMHC molecule of 2 S?1 or slower AND said polypeptide has at least a 45% identity and/or 55% similarity to a defined high-affinity ILT-like molecule AND said polypeptide inhibits CD8 binding to the given pMHC to a greater extent than a soluble truncated variant of Wild-Type ILT-2. Such high-affinity ILT-like molecules are useful, either alone or associated with a therapeutic agent, for the inhibition of cytotoxic T cell (CTL) responses.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: January 10, 2012
    Assignee: MediGene AG
    Inventors: Bent Karsten Jakobsen, Yi Li, Ruth Karen Moysey
  • ILT-2 (LIR1) VARIANTS WITH INCREASED AFFINITY FOR MHC CLASS I MOLECULES
    Publication number: 20110172168
    Abstract: The present invention provides ILT-2 variants having the property of binding to a given Class IpMHC with a KD of less than or equal to 1 ?M and/or an off-rate (Koff) of 2 S?1 or slower AND said polypeptide has at least a 45% identity and/or 55% similarity to SEQ ID NO: 19 AND said polypeptide inhibits CD8 binding to the given pMHC to a greater extent than the polypeptide SEQ ID NO: 3, CHARACTERISED IN THAT said polypeptide comprises an amino acid sequence selected from one of SEQ ID NOs 6 to 69. Such polypeptides are useful, either alone or associated with a therapeutic agent, for the inhibition of cyto-toxic T cell (CTL) responses.
    Type: Application
    Filed: November 24, 2006
    Publication date: July 14, 2011
    Applicant: MediGene Ltd.
    Inventors: Bent Karsten Jakobsen, Yi Li, Ruth Karen Moysey
  • POLYPEPTIDE MONOMERS AND DIMERS CONTAINING MUTATED ILT
    Publication number: 20100135997
    Abstract: The present invention provides monomeric and dimeric polypeptide fusions comprising mutated human ILT molecules and immunoglobulin Fc segments. Such compostions are useful, either alone or associated with a therapeutic agent, for targeting cells expressing Class I pMHC molecules.
    Type: Application
    Filed: November 8, 2007
    Publication date: June 3, 2010
    Applicant: MedGene Ltd.
    Inventors: Bent Karsten Jakobsen, Yi Li, Ruth Karen Moysey
  • Polypeptides
    Publication number: 20090208447
    Abstract: The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a KD for the said given Class I pMHC of less than or equal to 1 ?M and/or has an off-rate (koff) for the said given Class I pMHC molecule of 2 S?1 or slower AND said polypeptide has at least a 45% identity and/or 55% similarity to SEQ ID NO: 7 AND said polypeptide inhibits CD8 binding to the given pMHC to a greater extent than the polypeptide SEQ ID NO:3. Such polypeptides are useful, either alone or associated with a therapeutic agent, for the inhibition of cytotoxic T cell (CTL) responses.
    Type: Application
    Filed: May 19, 2006
    Publication date: August 20, 2009
    Applicant: MEDIGENE LIMITED
    Inventors: Bent Karsten Jakobsen, Yi Ll, Ruth Karen Moysey